Threshold Pharmaceuticals, Inc., based in South San Francisco,
California, is a research-driven biotechnology company dedicated to the discovery and development of tumor targeted therapies to improve the lives of patients with cancer.
- August 27, 2015
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
- August 11, 2015
- Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC)
- July 30, 2015
- Threshold Pharmaceuticals Reports Second Quarter 2015 Financial and Operational Results